Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2016	Jun. 30, 2016
Current Assets:
Cash and cash equivalents	$ 8,464,607	$ 13,203,625
Marketable securities	24,570,193	37,424,221
Accounts receivable, net of allowance for doubtful accounts of $64,767 at September 30, 2016 and $74,546 at June 30, 2016	584,410	513,992
Inventory	329,391	350,524
Other receivables		236,768
Prepaid expenses	1,794,282	1,038,155
Other current assets	358,368	183,820
Total current assets	36,101,251	52,951,105
Property and equipment, net of accumulated depreciation of $28,870,579 and $28,637,606 at September 30, 2016 and June 30, 2016, respectively	4,477,597	3,969,163
Other long-term assets	30,000	30,000
Total Assets	40,608,848	56,950,268
Current Liabilities:
Accounts payable and accrued expenses	14,118,979	15,188,189
Deferred revenues	206,275	235,372
Total current liabilities	14,325,254	15,423,561
Convertible senior notes – net of unamortized debt issuance costs of $2,463,148 at September 30, 2016 and $2,645,602 at June 30, 2016	97,536,854	97,354,398
Other liabilities	1,724,155	1,699,276
Commitments and Contingencies (Note 11)
Stockholders' Deficit:
Preferred stock, $.01 par value; authorized 10,000,000 shares; no shares issued and outstanding at September 30, 2016 and June 30, 2016
Common stock, $.01 par value; authorized 155,000,000 shares; issued 95,977,580 shares and outstanding 95,942,855 shares at September 30, 2016; issued 95,867,298 shares and outstanding 95,832,573 shares at June 30, 2016	959,775	958,672
Capital contributed in excess of par	312,093,494	311,320,651
Treasury stock, at cost: 34,725 shares at September 30, 2016 and at June 30, 2016	(458,370)	(458,370)
Accumulated deficit	(384,702,802)	(368,504,954)
Accumulated other comprehensive loss	(127,727)	(132,226)
Total Immunomedics, Inc. stockholders' deficit	(72,235,630)	(56,816,227)
Noncontrolling interest in subsidiary	(741,785)	(710,740)
Total stockholders’ deficit	(72,977,415)	(57,526,967)
Total Liabilities and Stockholders' Deficit	$ 40,608,848	$ 56,950,268